

7:00am – 8:00am Registration ♦ Continental Breakfast at Exhibit Hall

8:00 am Welcome & Introduction

Yehuda Handelsman, MD/ Chair
Pauline M. Camacho, MD/ AACE President**SESSION #1****Insulin Resistance Diabetes & Thrombosis****CHAIR:** Zachary Bloomgarden, MD/Bart Staels, PhD

8:15 am Resetting Insulin Resistance with FGF1

Ronald M. Evans, PhD

8:45 am The Global Diabetes Epidemic: Famines, Feast and Epigenetics

Paul Zimmet, MD, PhD

9:15 am The Non-Thrombotic Aspects of Hemostatic Processes: Should They Be Considered in the Management of Thrombosis? Peter J. Grant, MD

9:45 am **Q+A Panel Discussion & Clinical Implications****10:00 am – 10:30 am Refreshment Break at Exhibit Hall****SESSION #2****The Role of Incretin Hormones in Human Metabolism****CHAIR:** Ralph A. DeFronzo, MD / Vivian A. Fonseca, MD

10:30 am The Incretin Effect and the Incretin Hormones

Jens J. Holst, MD

11:00 am GLP-1-A Pleiotropic Hormone with Actions Independent of Glucose Homeostasis

Daniel J. Drucker, MD

11:30 am Rebuttal

Jens J. Holst, MD

11:45 am Rebuttal

Daniel J. Drucker, MD

12:00 pm–12:15pm **Q+A Panel Discussion & Clinical Implications:** GLP-1 Receptor Agonists & of Cardiovascular Disease – How?

Moderators Ralph A. DeFronzo, MD/ Vivian A. Fonseca, MD

12 :15 pm – 1:30 pm**POSTERS & EXHIBITORS RECEPTION – EXHIBIT HALL****SESSION #3****Insulin Resistance in the Aging Population****CHAIR:** Derek LeRoith, MD, PhD/ Daniel Einhorn, MD

1:30 pm Obesity in Older Adults

Samuel Klein, MD

2:00 pm Growth Hormone/IGF1 and Insulin Resistance in Older Population

Derek LeRoith, MD, PhD

2:30 pm Hypogonadism in Diabesity: Reversal of Insulin Resistance Following Testosterone Treatment

Paresh Dandona, MD, PhD

3:00 pm – 3:15pm **Q+A Panel Discussion & Clinical Implications****CONCURRENT SESSIONS****MEET THE EXPERT**

3 :15 pm – 4:15 pm

- ☐ **Gerald M. Reaven, MD** Insulin Resistance: Associated Abnormalities and Clinical Syndromes
- ☐ **Ralph A. DeFronzo, MD** Pathophysiologic Approach to Therapy in T2DM
- ☐ **Daniel Einhorn, MD** Paradigm shift in treating DM and obesity
- ☐ **Yehuda Handelsman, MD** Lipids – Consider Lower Goals

4:15 pm – 4:45 pm Refreshment Break at Exhibit Hall**SESSION #4****Sleep, Circadian Rhythm and Cardiovascular Risk****CHAIR:** Sonia Caprio, MD / Robert J. Chilton, DO

4:45 pm Can Childhood and Young Adult Studies Predict Later Cardiovascular Risk

Alan Sinaiko, MD

5:10 pm Sleep, Circadian Rhythms and Metabolism: The Inseparable Triad

Eve Van Cauter, PhD

5:40 pm–5:50pm **Q+A Panel Discussion & Clinical Implications****6:00 pm – 7:30 pm RECEPTION SATELLITE SYMPOSIUM****Management and Prevention of CVD in Metabolic Syndrome & Diabetes: Focus on PCSK9 Inhibitors**

6:00 pm Welcome and Introduction

Yehuda Handelsman, MD – Chair

6:05 pm Epidemiology and Pathophysiology of CVD in the High-Risk People with Obesity, Metabolic Syndrome and Diabetes

Zachary T. Bloomgarden, MD

6:25 pm PCSK9 Physiology in Lipids & Disorders, From Genetics to Discovery - Role in Cardiovascular Disease

Sergio Fazio, MD, PhD

6:45 pm The Development, Efficacy and Safety of the Monoclonal Antibodies PCSK9 Inhibitors

Evan A. Stein, MD, PhD

7:05 pm Panel - Q & A Lipids Goals in Therapy; Beyond Statins the Role of PCSK9 in the Treatment Algorithm of the Extreme High-Risk Patients

Faculty: Zachary T. Bloomgarden, MD; Sergio Fazio, MD, PhD; Evan Stein, MD, PhD; Robert J. Chilton, DO; Nikolaus Marx, MD
Moderator: Yehuda Handelsman, MD

7:25 pm Adjourn

Reception by MEEF

Supported by an Educational Grant from Amgen

7:30 pm –8:30 pm Welcome and Posters Reception - Exhibit Hall

7:00 am Registration ♦ Continental Breakfast at Exhibit Hall

8:00 am Summary of First Day

Zachary T. Bloomgarden, MD

SESSION #5**Endogenous Glucose Production and Beyond****CHAIR:** George Grunberger, MD / Peter J. Grant, MD

8:10 am The Multifaceted Control of Hepatic Glucose Uptake in Vivo

Alan D. Cherrington, PhD

8:40 am Primacy of Indirect Control by Insulin of Endogenous Glucose Production: Essential Roles of Adipose Tissues & the Kidneys **Richard N. Bergman, PhD**

9:10 am All You Need to Know about Glucagon and What You Did Not Know to Ask

Jens J. Holst, MD

9:40 am – 9:55 am **Q+A Panel Discussion & Clinical Implications****9:55 am – 10:25 am Refreshment Break at Exhibit Hall****AWARD PRESENTATION** By: Peter J. Grant, MD / Ralph A. DeFronzo, MD10:25 am **“Life Time Scientific Achievement Award”****KEY NOTE** Hyperinsulinemia: A Philanthropist Gone Awry

Gerald M. Reaven, MD

**SESSION #6****The Heart, and Atherosclerosis in Insulin Resistance****CHAIR:** Mark Kearney, MD / Alan Sinaiko, MD

11:10 am MTK NADPH Oxidases and Atherosclerosis in Insulin Resistance

Mark Kearney, MD

11:40 am Early Target Organ Changes in Youth Associated with Cardiovascular Risk Factors

Elaine M. Urbina, MD

12:10 pm The Insulin Resistant Myocardium the Role of PCSK9i and SGLT2i

Robert J. Chilton, DO

12:35pm – 12:45pm **Q+A Panel Discussion & Clinical Implications****1:00 pm – 2:00 pm****PRODUCT THEATER Non CME**

Examining Options to go Further in the Treatment of Adults with Type 2 Diabetes.

Lunch will be servedSupported by: **Janssen**

Speaker: Christian W. Mende, MD

SESSION #7**Dyslipidemia and Residual CVD Risk****CHAIR:** Ronald Krauss, MD / Paul Jellinger, MD

2:00pm Lipoprotein Predictors of Residual CVD Risk on Statin Therapy

Ronald M. Krauss, MD

2:30pm HDL and TG: Should We Care? Should We Treat?

Henry N. Ginsberg, MD

3:00pm – 3:15pm **Q+A Panel Discussion & Clinical Implications****SESSION #8****A Glimpse to the Future – What's in the Pipeline? (Non-CME)****CHAIR:** Ralph A. DeFronzo, MD / Christos Mantzoros, MD, PhD

3:15 pm Novo Nordisk

Stephen Gough, MD

3:35 pm Medimmune

Boaz Hirshberg, MD

3:55 pm Sanofi Aventis

Jay Edelberg, MD, PhD

4:15 pm - 4:45 pm Refreshment Break**SESSION #9****Dysglycemia and Heart Failure with Preserved Ejection Fraction (HFpEF) – Two Sides of the Same Coin?****CHAIR:** Nikolaus Marx, MD/ Mikhail Kosiborod, MD

4:45 pm Introduction and Background

Mikhail N. Kosiborod, MD

5:00 pm Diabetes, Obesity and Insulin Resistance Mechanistic Insights for “Diastolic Diabetic Cardiomyopathy”

Mansoor Husain, MD

5:30 pm The Role of the Diabetologist in the Management of CHF in Diabetes

Vivian A. Fonseca, MD

6:00 pm The Contemporary Approach to Management of HFpEF is “Repurposing” of Glucose-Lowering Medications the New Frontier?

Mikhail N. Kosiborod, MD

6:30 pm – 6:45pm **Q+A Panel Discussion & Clinical Implications:** Treatment Interventions of HFpEF– Why has Everything Failed- What is the Future?Panel: **Mansoor Husain, MD/ Vivian A. Fonseca, MD/ Robert J. Chilton, DO / Mark Kearney, MD**Moderators: **Nikolaus Marx, MD / Mikhail N. Kosiborod, MD****6:30pm – 8:00 pm ABSTRACT – ORAL PRESENTATION**Zachary T. Bloomgarden, MD **Chair** • Philip Levy, MD • Daniel Einhorn, MD • George Grunberger, MD

7:00 am **Registration ♦ Continental Breakfast at Exhibit Hall**7:45 am – 7:50 am **Oral Abstract Winners Presentation**7:50 am – 8:00 am **Summary of Second Day****Zachary T. Bloomgarden, MD****SESSION #10 A New Brave World: The Role of T2D Medication in Transforming CVD Risk Management in Diabetes?****CHAIR** Mikhail N. Kosiborod, MD / Yehuda Handelsman, MD

8:00 am Pioglitazone, Insulin Resistance and Atherosclerosis: Can You Teach an Old Dog New tricks?

Silvio E. Inzucchi, MD

8:30 am Do SGLT2 Inhibitors Prolong the Life of People with T2D How?

Nikolaus Marx, MD

9:00 am GLP-1 RA the "SUSTAINED new LEADER" for Prevention of CVD in Diabetes?

George Grunberger, MD9:30 am - 9:50am **Q+A Panel Discussion & Clinical Implications:** Do We Need a Shift from "HbA1c" to "CVD Risk" Focus in T2D Management?Panel: **Nikolaus Marx, MD / Silvio E. Inzucchi, MD / George Grunberger, MD / Peter J. Grant, MD**Moderators: **Mikhail Kosiborod, MD / Yehuda Handelsman, MD**9:50 am - 10:20 am **Refreshment Break at Exhibit Hall****AWARD PRESENTATION** By: Daniel Einhorn, MD / Tracey L. McLaughlin, MD10:20 am **"Distinguished Leader in Insulin Resistance"**
KEY NOTE NASH: Yesterday, Today and Tomorrow**Arun J. Sanyal, MD****Session #11 Fat and the Liver, the NASH Connection****CHAIR:** Arun J. Sanyal, MD / Jaime A. Davidson, MD

11:00 pm Effects of Lipid Administration on Key Molecules Related to Energy Homeostasis: Implications for NASH

Christos Mantzoros, MD, PhD

11:30 pm The PPAR-NASH Connection

Bart Staels, PhD12:00 pm – 12:10 pm **Q+A Panel Discussion & Clinical Implications****CONCURRENT WORKSHOPS****CLINICAL WORKSHOPS****Lunch will be served**

12:15 pm – 1:15 pm

- ☐ **Diabetes**
- ☐ **Lipids**
- ☐ **Hypertension, Salt Sensitivity, and the Kidney**
- ☐ **Obesity**

Jaime A. Davidson, MD / Philip Levy, MD
 Paul S. Jellinger, MD / Paul D. Rosenblit, MD
 Christian W. Mende, MD
 W. Timothy Garvey, MD

SESSION #12 Obesity, Fat and Pre Diabetes**CHAIR:** Samuel W. Cushman, PhD / W. Timothy Garvey, MD

1:15pm Role of the Adaptive Immune System in Human Obesity and Insulin Resistance

Tracey L. McLaughlin, MD

1:45 pm Diabetes, Obesity and the Central Role of the Adipocyte in Maintaining Systemic Homeostasis

Philipp E. Scherer, PhD

2:15 pm IGF VS IFG: Different Etiologies! Different Treatments!

Ralph A. DeFronzo, MD2:45 pm-3:00pm **Q+A Panel Discussion & Clinical Implications**3:00 pm – 3:10 pm **Refreshment Break****SESSION #13 Metabolic Effect of Obesity, and Emerging New Therapeutic Modalities****CHAIR** Tracey L. McLaughlin, MD / Samuel Klein, MD

3:10 pm Acute Metabolic Effects of High Fat Diet in Mice

Samuel W. Cushman, PhD

3:30 pm Glucose-Induced Insulin Resistance: A Treatable Defect in Diabetes and Now We Know the Mechanism!

W. Timothy Garvey, MD

4:00 pm Offspring of Mothers with Gestational Diabetes: A Pre Diabetic Condition

Sonia Caprio, MD

4:30 pm Endoscopic and Device Therapy for Obesity

Shelby Sullivan, MD5:00 pm **Adjourn**